|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
With Pfizer's need for tax savings and pipeline products, an offer is expected to hand Allergan shareholders a 30% premium.
Novel Oral Treatment Could Bring New Option to Large, Unsatisfied Market
Submission Supported by Four Pivotal Phase III Trials Conducted in Europe and North America With More Than 1,500 Patients
Company Executing on Commercial Launch of KYBELLA™ (deoxycholic acid) Injection
Drugmaker Allergan withholds guidance for future quarters, following its announcement last week that it's selling its generic drug business to Teva Pharmaceuticals.
Drugmaker Allergan is putting off issuing guidance for future quarters following the company's announcement last week that it's selling its generic drug business to Teva Pharmaceuticals.
On Thursday August 6, TheStreet will be covering the first Republican Presidential debates, earnings from drug manufacturer Allergan and media company Viacom, and jobless claims.
Recently Launched as KYBELLA(TM) in the U.S., BELKYRA(TM) Deoxycholic Acid Injection Improves Appearance and Profile of Moderate to Severe Submental Fullness or "Double Chin"
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of KYTHERA Biopharmaceuticals, Inc.
The most recent short interest data has been released by the NASDAQ for the 06/30/2015 settlement date, which shows a 4,141,874 share decrease in total short interest for Kythera Biopharmaceuticals, Inc. , to 1,897,697, a decrease of 68.58% since 06/15/2015.
The biotech sector has been one of the fastest growing sectors through June 30, 2015. Here are the 10 best biotech stocks this year.
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Kythera Biopharmaceuticals, Inc.
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of KYTHERA Biopharmaceuticals, Inc.
The Rosen Law Firm, a global investor rights law firm, announces that it is investigating the Board of Directors of Kythera Biopharmaceuticals Inc.
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased KYTHERA Biopharmaceuticals, Inc.
Cramer says BioMarin, Radius Health and Allergan are winners but stay away from Diageo.
The Federal Reserve statement, Greece, selling the dollar and investor confidence all had a hand, Cramer says.
Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of KYTHERA Biopharmaceuticals, Inc.
Cramer says Allergan dominates treatments for your face with its buy of Kythera Biopharmaceuticals but it's time to ring the register on newly public Wingstop.
The stock markets in the United States gained after the Federal Reserve indicated any interest rate hike would be gradual as Chairperson Janet Yellen wants to see more definitive evidence of economic ...
Stocks closed in the green on Wednesday, but not without something of a struggle as markets bounced around in narrow range-bound trading.
Here's a look at how to trade some of the most active stocks on Wall Street right now.
Stocks recover after the Federal Reserve keeps rates unchanged at its meeting on Wednesday.
Allergan plc, which is known for its Botox product, said June 17 it is acquiring Kythera Biopharmaceuticals Inc. in a cash and stock deal valued at approximately $2.1 billion.
Synergy Pharmaceuticals (SGYP) jumped in midday trading Wednesday after announcing its experimental drug for chronic constipation had achieved its primary goal.